Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C. Ruggeri B, et al. Cancer Res. 2003 Sep 15;63(18):5978-91. Cancer Res. 2003. PMID: 14522925
Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist.
Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, Zhao H, Ruggeri B. Dobrzanski P, et al. Among authors: ruggeri b. Cancer Res. 2004 Feb 1;64(3):910-9. doi: 10.1158/0008-5472.can-3430-2. Cancer Res. 2004. PMID: 14871820
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
Miknyoczki S, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, Ator M, Husten J, Deibold J, Hudkins R, Zulli A, Parchment R, Ruggeri B. Miknyoczki S, et al. Among authors: ruggeri b. Mol Cancer Ther. 2007 Aug;6(8):2290-302. doi: 10.1158/1535-7163.MCT-07-0062. Mol Cancer Ther. 2007. PMID: 17699724
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.
Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, Yang S, Angeles T, Emerson SG, Carroll M, Ruggeri B, Dobrzanski P. Hexner EO, et al. Among authors: ruggeri b. Blood. 2008 Jun 15;111(12):5663-71. doi: 10.1182/blood-2007-04-083402. Epub 2007 Nov 5. Blood. 2008. PMID: 17984313 Free PMC article.
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Dorsey BD, Iqbal M, Chatterjee S, Menta E, Bernardini R, Bernareggi A, Cassarà PG, D'Arasmo G, Ferretti E, De Munari S, Oliva A, Pezzoni G, Allievi C, Strepponi I, Ruggeri B, Ator MA, Williams M, Mallamo JP. Dorsey BD, et al. Among authors: ruggeri b. J Med Chem. 2008 Feb 28;51(4):1068-72. doi: 10.1021/jm7010589. Epub 2008 Feb 5. J Med Chem. 2008. PMID: 18247547
226 results